SunWay Biotech Co., LTD.
SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business. The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products. The company also researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus… Read more
SunWay Biotech Co., LTD. (1271) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.041x
Based on the latest financial reports, SunWay Biotech Co., LTD. (1271) has a cash flow conversion efficiency ratio of 0.041x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$132.38 Million) by net assets (NT$3.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SunWay Biotech Co., LTD. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how SunWay Biotech Co., LTD.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SunWay Biotech Co., LTD. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SunWay Biotech Co., LTD. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southern Rubber Industry JSC
VN:CSM
|
0.143x |
|
Coxon Precise Industrial Co Ltd
TW:3607
|
-0.017x |
|
Barem Ambalaj Sanayi ve Ticaret a.s.
IS:BARMA
|
0.232x |
|
Right Way Industrial Co Ltd
TW:1506
|
-0.009x |
|
Accuray Incorporated
NASDAQ:ARAY
|
-0.228x |
|
SYN-Tech Chem & Pharm Co Ltd
TWO:1777
|
0.099x |
|
DURECT CORP. DL-001
F:DC8A
|
N/A |
|
IF Bancorp Inc
NASDAQ:IROQ
|
0.018x |
Annual Cash Flow Conversion Efficiency for SunWay Biotech Co., LTD. (2020–2024)
The table below shows the annual cash flow conversion efficiency of SunWay Biotech Co., LTD. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$3.27 Billion | NT$156.92 Million | 0.048x | +174.72% |
| 2023-12-31 | NT$3.20 Billion | NT$55.98 Million | 0.017x | -88.17% |
| 2022-12-31 | NT$288.09 Million | NT$42.58 Million | 0.148x | -49.70% |
| 2021-12-31 | NT$547.05 Million | NT$160.76 Million | 0.294x | -24.92% |
| 2020-12-31 | NT$464.62 Million | NT$181.86 Million | 0.391x | -- |